EUCTR2019-003158-10-ITActive, not recruitingPhase 1
ong-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis - Long-term safety&tolerability of GSK2330672 as a treatment for cholestatic pruritus participants PBC
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT0 sites75 target enrollmentStarted: September 2, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 75
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Participants are eligible to be included in the study only if all the following criteria apply:
- •1. Participant must be 18 to 80 years of age inclusive, at the time of signing the informed consent in the participant’s parent trial BAT117213 or 201000
- •Type of Participant and Disease Characteristics
- •2. Participants with a diagnosis of PBC and a history of associated pruritus as evidenced by randomization into a prior eligible linerixibat clinical trial(BAT117213 or 201000)
- •3. Participants must have completed the main treatment period in a prior eligible linerixibat clinical trial (BAT117213 or 201000)
- •4. Male or female
- •Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Contraception by male participants or male partners of female participants is not required in this protocol
- •a. Female Participants:
- •-A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
- •o Is not a woman of childbearing potential (WOCBP)
- •o Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, as described in [Appendix 4] of Protocol, during the intervention period and for at least 4 weeks, after the last dose of study intervention. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention
- •o A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention
- •o If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive
- •-Additional requirements for pregnancy testing during and after study intervention are listed in [Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information] of Protocol
- •-The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy
- •-Informed Consent
- •5. Capable of giving signed informed consent as described in [Appendix 1] of protocol, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 65
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
Exclusion Criteria
- •Participants are excluded from the study if any of the following criteria apply:
- •Medical Conditions
- •1. Screening total bilirubin >2x ULN. Total bilirubin >2x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%
- •2. Screening ALT or aspartate aminotransferase (AST) >6x ULN
- •3. Screening estimated glomerular filtration rate (eGFR) <45 mL/min/1.73m² based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
- •4. History or presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy or ascites)
- •5. Presence of actively replicating viral hepatitis B or C (HBV, HCV) infection and/or confirmed hepatocellular carcinoma or biliary cancer
- •Note: Other hepatic conditions (e.g., primary sclerosing cholangitis (PSC), alcoholic liver disease, autoimmune hepatitis, non-alcoholic steatohepatitis [NASH] are permitted if PBC is the dominant liver injury in the investigator’s opinion
- •6. Recent or current clinically significant diarrhea in the Investigator’s medical opinion
- •7. Current symptomatic cholelithiasis or inflammatory gallbladder disease is exclusionary. Participants with history of cholecystectomy =3 months before screening may be eligible for enrollment
- •8. Current diagnosis or previous diagnosis of colorectal cancer
- •9. Any current medical condition (e.g. psychiatric disorder, senility or dementia), which may affect the participant’s ability to comply with the protocol specified procedures
- •Prior/Concomitant Therapy
- •10. Use of Obeticholic acid: within 8 weeks prior to the date of the screening visit and may not restart until after the end of the study or study withdrawal. [Rationale: The potential for a Drug-Drug Interaction (DDI) between obeticholic acid and linerixibat has not been determined. A DDI study assessing the concomitant use of OCA and linerixibat is planned and depending on those results this OCA exclusion may be removed]
- •11. Administration of any other IBAT inhibitor in the 1 month prior to screening
- •[Rationale: Effects of another IBAT inhibitor may confound interpretation of the linerixibat safety and tolerability profile]
- •Prior/Concurrent Clinical Study Experience
- •12. Current enrollment or participation in any other clinical study (except for 201000)
- •involving an investigational study treatment within 8 weeks prior to the screening visit
- •Note: For participants coming from the 201000 study there is no specified waiting period before enrollment into this safety study.
- •Diagnostic assessments
- •13. QTc >480 msec
- •NOTES: The QTc is the QT interval corrected for heart rate according to Bazett’s formula (QTcB), Frederica’s formula (QTcF), and/or another method. It is either machine-read or manually over-read
- •The specific formula used to determine eligibility and discontinuation for an individual participant should be determined prior to initiation of the study and maintained for individual participants throughout study participation. The specific QT correction formula used must be specified in the eCRF
- •A QTc >480 msec (12-lead ECG) at screening is exclusionary
- •Note: The QT interval will be assessed at screening and at each long visit (yearly) by 12-Lead ECG. QTc stopping criteria are established for this study and are detailed in [Section 7.1.2] of Protocol
- •Other Exclusions
- •14. History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >21 units for males or >14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (~240 m
Investigators
Similar Trials
Active, not recruiting
Phase 1
inerixibat Long-term Safety and Tolerability Study (LLSAT)Moderate to Severe Pruritus (itching) caused by primary biliary cholangitis (PBC)MedDRA version: 21.1Level: PTClassification code 10064190Term: Cholestatic pruritusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.0Level: PTClassification code 10080429Term: Primary biliary cholangitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-003158-10-PLGlaxoSmithKline Research & Development Ltd75
Active, not recruiting
Phase 1
inerixibat Long-term Safety and Tolerability StudyModerate to Severe Pruritus (itching) caused by primary biliary cholangitis (PBC)MedDRA version: 21.1Level: PTClassification code 10064190Term: Cholestatic pruritusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.0Level: PTClassification code 10080429Term: Primary biliary cholangitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-003158-10-GBGlaxoSmithKline Research & Development Ltd75
Recruiting
Phase 1
Ph 3a, linerixibat, Long term safety and tolerability study in pts with PBCCholestasisMedDRA version: 21.0Level: PTClassification code: 10080429Term: Primary biliary cholangitis Class: 100000004871MedDRA version: 21.1Level: PTClassification code: 10064190Term: Cholestatic pruritus Class: 100000004858CTIS2023-503465-33-00Glaxosmithkline Research & Development Limited292
Active, not recruiting
Phase 1
inerixibat Long-term Safety and Tolerability Study (LLSAT)Moderate to Severe Pruritus (itching) caused by primary biliary cholangitis (PBC)MedDRA version: 24.1Level: PTClassification code 10064190Term: Cholestatic pruritusSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 21.0Level: PTClassification code 10080429Term: Primary biliary cholangitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-003158-10-GRGlaxoSmithKline Research & Development Ltd295
Recruiting
Phase 3
inerixibat Long-term Safety, and Tolerability StudyJPRN-jRCT2080225120GlaxoSmithKline K.K.305